Sarcopenia in chronic kidney disease: what have we learned so far?
Sabatino A, Cuppari L, Stenvinkel P, Lindholm B, Avesani CM. · 2021
Read Sarcopenia in chronic kidney disease: what have we learned so far? by Sabatino A, Cuppari L, Stenvinkel P, Lindholm B, Avesani CM. (2021) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc8357704.txt.
Introduction
Sabatino and co-authors survey sarcopenia in chronic kidney disease and what is known so far. Irwin Rosenberg coined the term in 1988 for muscle loss in old age. The meaning has since widened.
It now covers lost strength and poor physical performance too. Diagnosis rests on low muscle mass plus low function. Kidney patients show the condition often. It tracks with worse health outcomes in that group. The review gathers how sarcopenia appears in kidney care. Nutrition and exercise angles are weighed. Awareness is the first step the authors press.
Catalog record
| CREATOR | Sabatino A, Cuppari L, Stenvinkel P, Lindholm B, Avesani CM. |
|---|---|
| YEAR | 2021 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 99 KB |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |
Browse the full library · About the Tower of Babel
Full text
The opening of the work, from the library's hosted text:
Sarcopenia in chronic kidney disease: what have we learned so far? By Alice Sabatino, Lilian Cuppari, Peter Stenvinkel, Bengt Lindholm, Carla Maria Avesani Published in: Journal of Nephrology DOI: 10.1007/s40620-020-00840-y ABSTRACT Abstract The term sarcopenia was first introduced in 1988 by Irwin Rosenberg to define a condition of muscle loss that occurs in the elderly. Since then, a broader definition comprising not only loss of muscle mass, but also loss of muscle strength and low physical performance due to ageing or other conditions, was developed and published in consensus papers from geriatric societies. Sarcopenia was proposed to be diagnosed based on operational criteria using two components of muscle abnormalities, low muscle mass and low muscle function. This brought awareness of an important nutritional derangement with adverse outcomes for the overall health. In parallel, many studies in patients with chronic kidney disease (CKD) have shown that sarcopenia is a prevalent condition, mainly among patients with end stage kidney disease (ESKD) on hemodialysis (HD). In CKD, sarcopenia is not necessarily age-related as it occurs as a result of the accelerated protein catabolism from the disease and from the dialysis procedure per se combined with low energy and protein intakes. Observational studies showed that sarcopenia and especially low muscle strength is associated with worse clinical outcomes, including worse quality of life (QoL) and higher hospitalization and mortality rates. This review aims to discuss the differences in conceptual definition of sarcopenia in the elderly and in CKD, as well as to describe etiology of sarcopenia, prevalence, outcome, and interventions that attempted to reverse the loss of muscle mass, strength and mobility in CKD and ESKD patients. Keywords: Sarcopenia, Chronic kidney disease, End stage kidney disease, Skeletal muscle mass, Muscle strength, Physical performance INTRODUCTION Loss of muscle mass is a prevalent complication in patients with chronic kidney disease (CKD) and especially in those with end stage kidney disease (ESKD) [1–3]. The causes are diverse and ultimately converge to increased protein degradation and reduced protein synthesis, resulting in a state of negative protein balance [4]. This condition eventually leads to a nutritional disturbance known as protein energy wasting (PEW) that for long has been mostly attributed to malnutrition [5]. In addition to PEW/malnutrition, the terms sarcopenia and cachexia denote nutritional derangements that are related to the loss of muscle mass (wasting) that often is present in CKD. These conditions share common criteria and clinical outcome (Fig. 1) but have distinct definitions. Pure malnutrition is the loss of body weight, muscle mass and body fat due to insufficient energy and nutrient intake, while PEW has similar criteria, but with low-grade inflammation as an additional etiological condition [5]. Sarcopenia, on the other hand, is understood as the concomitant loss of muscle mass and muscle strength that occurs with aging. Cachexia is a syndrome that is present in diseases with chronic inflammation and increased breakdown of muscle proteins, such as in cancer, and is characterized by severe muscle loss that may or may not be accompanied by loss of body fat [6]. These nutritional abnormalities may occur concomitantly depending on the severity of the nutritional impairment. As for example, a patient with malnutrition/PEW may also present sarcopenia, but not necessarily cachexia; while a patient with cachexia may have malnutrition and sarcopenia. [Figure: Criteria and clinical outcome of malnutrition/protein energy wasting (PEW), sarcopenia, caquexia and muscle wasting in chronic kidney disease] The interest in sarcopenia increased in 2010, with the publication of the sarcopenia consensuses from different societies focusing mainly on the geriatric population [6–10]. Since then, the subject of sarcopenia got the attention of other medical specialties as a condition also present in clinical settings, independent of ageing. Since the publication of the first Sarcopenia Consensus from the European Working Group for Sarcopenia for Older People (EWGSOP) [6], a considerable amount of studies including CKD and ESKD patients on dialysis and kidney transplant recipients has been published. Now is time to analyze the strengths, flaws and applicability of the sarcopenia concept and its relevance for renal care management. This review aims to go through the conceptual definition of sarcopenia, its etiology, prevalence, association with clinical outcomes, and how it is affected by interventions aiming at improving muscle mass, muscle strength and mobility in CKD and ESKD patients. SARCOPENIA: DEFINITION, ETIOLOGY, OPERATIONAL CRITERIA AND METHODS OF ASSESSMENT The muscle tissue is one of the main organs in the body. The skeletal muscle is the largest component, but other types, including smooth muscle and cardiac muscle are also part of the muscle compartment. The loss of muscle mass, especially of skeletal muscle mass, is directly associated with diminished strength and indirectly associated with worse quality of life (QoL), increased vulnerability to undesirable outcomes such as falls, loss of independency and, ultimately, higher hospitalization rates and mortality [11]. To the best of our knowledge, Macdonald Critchley in 1931, a neurologist in London, was the first in modern scientific literature to connect the loss of skeletal muscle to ageing when observing that the musculature tends to decrease in the elderly [12]. Since then, many observations were reported regarding the changes in the musculature and body fat that occurs with ageing [13]. These changes refer mainly to an interrelated loss in muscle quantity (mass and volume), decrease in muscle strength and muscle quality, and increase in body fat [14]. Most studies assessing changes in muscularity over life are cross-sectional and the results indicate an estimated decrease in muscle mass of about 1 to 2% per year after the age of 50 years, which tends to further increase after 70 years of age accounting for a total accumulated loss of about 40% between the age of 20 and 70 years [13]. Longitudinal studies including elderly subjects confirm these cross-sectional findings. In septuagenarian individuals, Delmonico et al. [14] demonstrated an annual decrease in muscle area of − 4.9 ± 7.4% in men and of − 3.4 ± 7.9% in women after > 5 years of follow up. A similar result was found by Cameron et al. [15] also in septuagenarian recreationally active men and women, in whom the decrease in thigh lean mass assessed by magnetic resonance imaging (MRI) and whole body lean mass assessed by dual energy x-ray absorptiometry (DXA) was approximately 5% during 5 years. These changes in muscularity have been termed sarcopenia by Irwin Rosenberg in 1988, which comes from Greek and means sarx = flesh and penia = loss [16]. For many years, sarcopenia was mostly understood as loss of muscle mass that occurs with ageing; however, studies showed that not only the muscle quantity, but also muscle strength and physical performance decreases during life [17, 18]. These new findings, conveyed in five sarcopenia consensus papers from different medical societies [6–10], resulted in a common definition in which sarcopenia is a “syndrome characterized by progressive and generalized loss of muscle mass and strength with a risk of adverse outcomes including physical disability, poor QoL and death” [6]. The operational criteria proposed were similar among the consensus reports: sarcopenia is diagnosed when low muscle mass (by measurements of muscle quantity) and low muscle function (by measurements of muscle strength and/or physical performance) occur concomitantly [6–10]. Out of the aforementioned consensuses, the EWGSOP categorized